Press releases
- ASCO 2024 | Ascentage Pharma to Present Four Studies, Including an Oral Report Featuring the Latest Data of Olverembatinib in SDH-Deficient GIST
- AACR 2024 | Ascentage Pharma Presents Results from Three Studies at 2024 American Association of Cancer Research Annual Meeting
- AACR 2024 | Ascentage Pharma to Present Three Preclinical Studies at 2024 American Association of Cancer Research Annual Meeting
- Global Registrational Phase III Study of Olverembatinib (HQP1351) Cleared by FDA
Key statistics
On Friday, Ascentage Pharma Group International (36X:FRA) closed at 2.18, 17.20% above the 52 week low of 1.86 set on Apr 19, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.16 |
---|---|
High | 2.18 |
Low | 2.16 |
Bid | 2.10 |
Offer | 2.28 |
Previous close | 2.14 |
Average volume | 0.00 |
---|---|
Shares outstanding | 290.21m |
Free float | 212.89m |
P/E (TTM) | -- |
Market cap | 5.02bn HKD |
EPS (TTM) | -3.53 HKD |
Data delayed at least 15 minutes, as of May 03 2024 08:59 BST.
More ▼